Mantle Cell Lymphoma | Specialty

Using BTK Inhibitors in Community Practice

March 4th 2019

BTK Combination Strategies for B-Cell Malignancies

March 4th 2019

BTK Inhibitors in Chronic Lymphocytic Leukemia

March 4th 2019

New and Emerging BTK Inhibitors in Mantle Cell Lymphoma

March 4th 2019

First-Generation BTK Inhibition in Mantle Cell Lymphoma

March 4th 2019

BTK Inhibitors in Waldenstrom Macroglobulinemia

March 4th 2019

Resistance to BTK Inhibitors in B-Cell Malignancies

March 4th 2019

BTK Inhibitors Explored in B-Cell Malignancies

March 4th 2019

Targeting BTK in B-Cell Malignancies

March 4th 2019

Genomic Profiling in Chronic Lymphocytic Leukemia

March 4th 2019

Diagnosing Waldenstrom Macroglobulinemia

March 4th 2019

Watch-and-Wait Approach Can Be Beneficial Strategy in MCL

March 3rd 2019

Prognostic indices for mantle cell lymphoma are good for classifying patients but do little in the way of guiding treatment, and often the best course of action is to watch and wait.

Dr. Wang Discusses Promise of Venetoclax in MCL

March 2nd 2019

Michael Wang, MD, a professor in the Department of Lymphoma and Myeloma at The University of Texas MD Anderson Cancer Center, discusses the promise of venetoclax in the treatment of patients with relapsed/refractory mantle cell lymphoma.

Ibrutinib/Palbociclib Combo Shows Activity in Previously Treated MCL

February 21st 2019

Combining ibrutinib with the CDK4/6 inhibitor palbociclib appeared to be well tolerated and active in patients with previously treated mantle cell lymphoma.

Novel Frontline Regimen Improves PFS in Older Patients With MCL

February 21st 2019

The 4-drug combination of rituximab, bendamustine, bortezomib, and dexamethasone was found to improve progression-free survival and demonstrated a tolerable safety profile as frontline treatment for patients with mantle cell lymphoma who are ≥65 years.

Dr. Patel on Induction in Patients With Mantle Cell Lymphoma

February 19th 2019

Krish Patel, MD, medical oncologist, Swedish Cancer Institute, discusses induction therapy in patients with mantle cell lymphoma (MCL).

Dr. Goy on Promising Data With Acalabrutinib in MCL

February 19th 2019

Andre Goy, MD, MS, chief, Division of Lymphoma, chairman and director, John Theurer Cancer Center, discusses promising data with acalabrutinib in the treatment of patients with mantle cell lymphoma.

Dr. Wang on Updated Data With Single-Agent Acalabrutinib in MCL

February 14th 2019

Michael Wang, MD, a professor in the Department of Lymphoma and Myeloma at The University of Texas MD Anderson Cancer Center, discusses updated data with single-agent acalabrutinib in mantle cell lymphoma.

Dr. Patel on Ibrutinib in Real-World Setting Versus Clinical Trials

February 13th 2019

Krish Patel, MD, medical oncologist, Swedish Cancer Institute, discusses a study looking at real-world benefit of BTK inhibitors versus what is seen in clinical trials for patients with mantle cell lymphoma.

Dr. Rule on Treatment Approaches for Patients With p53-Mutated MCL

February 9th 2019

Simon Rule, MD, PhD, professor of hematology, Plymouth University Medical School, United Kingdom, discusses treatment approaches for patients with p53-mutated mantle cell lymphoma (MCL).